linjc16/ctgov huggingface dataset:
Incidental Cancer in Familial Adenomatous Polyposis

Study Overview
=================
Brief Summary
-----------------
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.

Detailed Description
-----------------
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. The files of patients diagnosed with FAP who underwent surgery in our clinic between 2010 and 2020 were retrospectively reviewed. Definitive surgery was performed in patients with histopathological malignancy identified in colonoscopic biopsies in the preoperative period, while prophylactic surgery was performed in patients without malignancy. The incidence of incidental malignancy in histopathological specimens from patients who underwent prophylactic colectomy was determined. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.

Official Title
-----------------
Incidental Cancer in Colectomy Specimens From Patients With Familial Adenomatous Polyposis

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with Familial Adenomatous Polyposis Exclusion Criteria: did not receive surgical treatment data deficiencies
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| incidental cancer<br>familial adenomatous polyposis with incidental cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidental cancer | Familial Adenomatous Polyposis with cancer | 2 or 3 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenoma, familial adenomatous polyposis, colectomy, rectum, cancer
Artificial Intelligence (AI) in Cardiotocography (CTG) Interpretation

Study Overview
=================
Brief Summary
-----------------
The project leaders plan to create a clinical decision support (CDS) system by programming a self-learning software to analyze the cardiotocography (CTG) traces in the - already existing - database from the maternity department of the Inselspital Berne. The project leaders will process and analyze all clinical outcomes of the estimated 10000-15000 eligible patient records. CSEM will design, develop, and validate several AI architectures with the intend to create the CDS system. The AI would learn to assist on this task by training machine learning (ML) algorithms. The main purpose of the AI-CDS will be to determine the best fetal extraction moment during labor, based on a self-learning approach, as a superhuman support tool for obstetricians in decision making during labor.

Official Title
-----------------
Introduction of Artificial Intelligence (AI) and Machine Learning in Cardiotocography (CTG) Interpretation to Improve Clinical Use

Conditions
-----------------
To Introduce Artificial Intelligence (AI) and Machine Learning in Cardiotocography (CTG) Interpretation to Improve Clinical Use

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CTG-registrations of patients with singleton pregnancies during labour from 01.01.2006 to 31.12.2019 Gestational age ≥ 24+0 weeks Age ≥ 18 years Written informed consent Exclusion Criteria: Documented refusal Multiple pregnancies CTG-registrations of planned caesarean sections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Superior prediction of fetal morbidity through the self-learning CDS system than if performed by obstetricians alone, especially in regards to specificity. |  | 3 months |
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Study Overview
=================
Brief Summary
-----------------
We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Conditions
-----------------
Pelvic Inflammatory Disease

Intervention / Treatment
-----------------
* Drug: Moxifloxacin
* Drug: Ofloxacin
* Drug: Metronidazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women diagnosed uncomplicated PID Patients age are between 14 with 45 Pelvic tenderness and vaginal discharge Exclusion Criteria: Urinary Tract Enfections Tubo-ovarian abscess and complicated PID Hıstory of antibiotics treatment Other pelvic pain causes Endometriosis Delivery,abortion and surgery within last months

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: moxifloxacin Group<br>Treatment at uPID with moxifloxacin | Drug: Moxifloxacin<br>* daily 400 mg moksifloksasin<br>* Other names: new generetaion flouroquinolon antibiotics;|
| Placebo Comparator: Ofloxacin Group<br>Treatment at uPID with Ofloxacin plus metronidazole | Drug: Ofloxacin<br>* daily 800 mg oflaksasin plus 1000 mg metronidazol treatment<br>* Other names: floroquinolon antibiotics;Drug: Metronidazole<br>* daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID<br>* Other names: anaerobic antibiotics;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinically cure |  | 21 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbiological cure |  | 21 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment, moksifloksasin
First Responder Resiliency Program During COVID-19

Study Overview
=================
Brief Summary
-----------------
Evaluating a wellness program developed to provide effective sustainable solutions for medical professionals providing care to COVID-19 pandemic patients.

Detailed Description
-----------------
Providing mindfulness training at specific time points during study participation with an emphasis on integrating physical and mental health management. The phase-based program delivers individualized, data-driven and quantifiable solutions that directly address pain points impacting healthcare professionals and organizations.

Official Title
-----------------
First Responder Resiliency Program for Health Care Professionals During a Pandemic

Conditions
-----------------
Resilience, Stress, Sleep

Intervention / Treatment
-----------------
* Behavioral: Resilience Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older at the time of consent Frontline healthcare professional Have access to an Apple or Android device Not pregnant by subject self-report at time of consent Have the ability to provide informed consent Have no contraindicating comorbid health condition as determined by the clinical investigators Exclusion Criteria: Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis Currently (within the past 3 weeks) been undergoing an additional program (e.g. CAM) to improve quality of life or sleep Currently (within 3 weeks) been enrolled in another clinical or research program (e.g. CAM) which intervenes on the patients' QOL, stress or sleep An unstable medical or mental health condition as determined by the physician investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Resilience Program<br>a 4 week program focused on improving resilience | Behavioral: Resilience Program<br>* Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in biometric trends | changes in oxygen saturation | 4 weeks |
Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

Study Overview
=================
Brief Summary
-----------------
This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).

Detailed Description
-----------------
This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH.

Conditions
-----------------
Congenital Adrenal Hyperplasia

Intervention / Treatment
-----------------
* Drug: Nifedipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with Congenital Adrenal Hyperplasia (CAH) normal ECG during baseline evaluation Exclusion Criteria: history of liver disease, or elevated liver function tests history of cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nifedipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Botulinum Toxin Injection to Prevent Ventricular Arrhythmias

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in left ventricle for preventing ventricular arrhythmias.

Official Title
-----------------
Endomyocardial Botulinum Toxin Injection Can Prevent Ventricular Arrhythmias: Pilot Study

Conditions
-----------------
Symptomatic Ventricular Asystolia, Ventricular Tachycardia

Intervention / Treatment
-----------------
* Drug: Botulinum Toxin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic ventricular arrhythmias drug-resistance unsuccessful one or more ablation procedure with future unreasonable tries Exclusion Criteria: Previous heart surgery and AF ablation procedure Emergency CABG Unstable angina or heart failure Use antiarrhythmic drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone) Requiring concomitant valve surgery Left ventricle ejection fraction <35% Unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BT injection<br> | Drug: Botulinum Toxin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| freedom of ventricular arrhythmias |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serious adverse events |  | 1 year | 
| time to recurrence of ventricular arrhythmias |  | 1 year |
Respiratory Motion Correction of Cardiac Combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI)

Study Overview
=================
Brief Summary
-----------------
This study evaluates the possibility of Magnetic Resonance Imaging (MRI) based respiratory motion correction of simultaneously acquired cardiac Positron Emission Tomography (PET) images.

Official Title
-----------------
Respiratory Motion Correction of Cardiac Combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI)

Conditions
-----------------
Cardiac Imaging

Intervention / Treatment
-----------------
* Diagnostic Test: Cardiac PET/MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18F-FDG injection for clinical diagnostic PET/MRI or PET/CT Exclusion Criteria: Diet-suppressed myocardial uptake of 18F-FDG General exclusion criteria for MRI (i.e. metallic implants, claustrophobia, pregnancy, etc.) Not willing to be informed about incidental findings

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target-to-background ratio (TBR) |  | 15-20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Signal-to-noise ratio (SNR) |  | 15-20 minutes |
Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum HCV RNA, changes in ALT and safety parameters.

Official Title
-----------------
Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Conditions
-----------------
Chronic Hepatitis C

Intervention / Treatment
-----------------
* Drug: Nitazoxanide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years. Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA. Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis. Exclusion Criteria: Patients unable to take oral medications. Use of interferon alpha within 90 days or ribavirin within 30 days prior to enrollment. Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. Any investigational drug therapy within 30 days prior to enrollment. Patients with other causes of liver disease. Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus based on enzyme immunoassay. Patients with history of alcoholism or with an alcohol consumption of >40 grams per day. Patients who are clinically unstable. Patients with any concomitant condition that, in the opinion of the investigator would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed. History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nitazoxanide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Virologic response |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sustained virologic response |  |  | 
| Quantitative serum HCV RNA |  |  | 
| Changes in ALT |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Hepatitis C
A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
This study will investigate the influence of MK0859 on ambulatory blood pressure, and how safe and tolerable MK0859 is on the subjects This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions
-----------------
Ambulatory Blood Pressure

Intervention / Treatment
-----------------
* Drug: MK0859


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: You are between the ages of 45-75 You are a man or non-pregnant woman You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication Exclusion Criteria: You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months You have used St. John's Wort or any products that include it within the last 2 weeks You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks You have a history of drug allergies (anaphylaxis, angioedema) You have taken an investigational drug in another clinical trial within the last 4 weeks You have a history of cardiovascular disease including hypertension (high blood pressure) You have a history of renal disease You have a history of gall bladder disease or have had abnormal liver function tests You have a history of drug or alcohol abuse You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0859|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |